Prolia and Ryaltris adjust drug pricing
By Lee, Tak-Sun | translator Kim, Jung-Ju
24.04.22 16:57:45
가나다라
0
Prolia, osteoporosis treatment, voluntarily reduces drug pricing in consideration of National Health Insurance finance
Ryaltris, priced 30% higher than the expected claim amount, has agreed to reduce its pricing.
▲Prolia.
Amgen Korea and Chong Kun Dang Pharmaceutical will voluntarily reduce the price of 'Prolia,' which they are jointly selling.
As the government expanded the administration guidance of osteoporosis medicines, Prolia, which is expected to see an increase in sales following the reimbursement expansion, voluntarily adjusted the ceiling price of the drug.
Prolia recorded sales of KRW 151.1 billion last year (according to IQVIA), ranking second in the domestic pharmaceutical sales in Korea, following Keytruda.
Some products, such as Yuhan’s 'Ryaltris Nasal Spray,' will lower the ceiling price due to increased usage.
According to industry sources on the 22nd
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)